Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.
Shares of Eli Lilly (LLY) jumped 8% in pre-market trading on Wednesday, after the company reported better-than-expected fourth-quarter results and issued a revenue guidance between $80 billion and $83 billion for fiscal 2026, significantly above fiscal 2025 revenue.
Fourth-quarter revenue surged 43% to $19.3 billion, driven by volume growth from Mounjaro and Zepbound – signalling sustained momentum in its obesity and diabetes portfolio. Analysts had expected a revenue of $17.86 billion, according to Fiscal.ai data. Meanwhile, Q4 earnings increased by 51% to $7.39 per share on a reported basis, compared to Street estimates of $7.22 per share.
For the full year, Eli Lilly’s revenue grew 45% to $65.18 billion. LLY expects earnings of $33.50 to $35.00 per share for the full year 2026.
Read updates on this developing story on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
-
'Keeping The Flag Flying High...': Virat Kohli Applauds RCB Women's Historic Triumph Over Delhi Capitals At WPL 2026
-
'Even The US Is Falling Behind': Larry Fink Praises Modi Govt's Rupee Digitisation & Commerce Transformation in India
-
Pariksha Pe Charcha 2026: 'Collaborative Learning Helps Everyone Improve' PM Modi Shares His Mantra In PPC
-
CTET 2026 Begins Tomorrow: Over 25 Lakh Candidates To Appear For Exam; Paper 1 To Begin At 9:30 AM; Two Shifts Scheduled
-
Malayalam Actor Maniyanpilla Raju Booked In Hit-And-Run Case Injuring Two Youths In Thiruvananthapuram, Fled After Car Hit Bike
